PE20180232A1 - DERIVED FROM INDOL MONO OR DISUSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUE - Google Patents
DERIVED FROM INDOL MONO OR DISUSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUEInfo
- Publication number
- PE20180232A1 PE20180232A1 PE2017002377A PE2017002377A PE20180232A1 PE 20180232 A1 PE20180232 A1 PE 20180232A1 PE 2017002377 A PE2017002377 A PE 2017002377A PE 2017002377 A PE2017002377 A PE 2017002377A PE 20180232 A1 PE20180232 A1 PE 20180232A1
- Authority
- PE
- Peru
- Prior art keywords
- mono
- dengue
- disustituted
- indol
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a un compuesto de formula (I), donde: R1 es H, CH3, OCF3 entre otros; R2 es F, H OCH3 entre otros y R3 es H o CH3. Este compuesto se refiere a un grupo indol mono o disustituido, que tiene una forma estereo isomerica, una sal, solvato o polimorfo farmaceuticamente aceptable. Dichos compuestos se usan para inhibir la replicacion del virus del dengue. Tambien se refiere preparaciones de composiciones para su uso como medicamento para la prevencion o tratamiento de infecciones virales por dengue.Referred to a compound of formula (I), where: R1 is H, CH3, OCF3 among others; R2 is F, H OCH3 among others and R3 is H or CH3. This compound refers to a mono or disubstituted indole group, having a pharmaceutically acceptable stereo isomeric form, a salt, solvate or polymorph. Said compounds are used to inhibit dengue virus replication. It also refers to compositions preparations for use as a medicament for the prevention or treatment of dengue viral infections.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166900 | 2015-05-08 | ||
| EP16163342 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180232A1 true PE20180232A1 (en) | 2018-01-31 |
Family
ID=56026812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001440A PE20221579A1 (en) | 2015-05-08 | 2016-05-04 | INDOL MONO DERIVATIVES OR DISUBSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUE |
| PE2017002377A PE20180232A1 (en) | 2015-05-08 | 2016-05-04 | DERIVED FROM INDOL MONO OR DISUSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUE |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001440A PE20221579A1 (en) | 2015-05-08 | 2016-05-04 | INDOL MONO DERIVATIVES OR DISUBSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUE |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US10696632B2 (en) |
| EP (2) | EP3294738B1 (en) |
| JP (4) | JP6752821B2 (en) |
| KR (2) | KR102610493B1 (en) |
| CN (3) | CN113045476A (en) |
| AU (2) | AU2016259677B2 (en) |
| BR (1) | BR112017023904A2 (en) |
| CA (1) | CA2981845C (en) |
| CL (1) | CL2017002817A1 (en) |
| CO (1) | CO2017012381A2 (en) |
| CR (2) | CR20170490A (en) |
| CY (1) | CY1124548T1 (en) |
| DK (1) | DK3294738T3 (en) |
| EA (1) | EA034978B1 (en) |
| EC (2) | ECSP17073878A (en) |
| ES (2) | ES2877404T3 (en) |
| GT (1) | GT201700234A (en) |
| HK (2) | HK1252446A1 (en) |
| HR (1) | HRP20210675T1 (en) |
| HU (1) | HUE054724T2 (en) |
| IL (2) | IL255430B (en) |
| JO (2) | JOP20160086B1 (en) |
| LT (1) | LT3294738T (en) |
| MD (1) | MD3294738T2 (en) |
| MX (2) | MX2020011156A (en) |
| NI (1) | NI201700137A (en) |
| PE (2) | PE20221579A1 (en) |
| PH (1) | PH12017502000A1 (en) |
| PL (1) | PL3294738T3 (en) |
| RS (1) | RS62029B1 (en) |
| SG (1) | SG10201900315SA (en) |
| SI (1) | SI3294738T1 (en) |
| SV (1) | SV2017005557A (en) |
| TW (2) | TWI725969B (en) |
| UA (1) | UA121332C2 (en) |
| UY (2) | UY36674A (en) |
| WO (1) | WO2016180696A1 (en) |
| ZA (2) | ZA201707524B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (en) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| SG11201808138YA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole derivatives as dengue viral replication inhibitors |
| MA44498A (en) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | SUBSTITUTED INDOLINE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| EA201892200A1 (en) * | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | SUBSTITUTED DERIVATIVE COMPOUNDS OF INDOL AS AN INGIBITORS FOR DENG VIRUS REPLICATION INHIBITORS |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| KR102625991B1 (en) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted indoline derivatives as dengue virus replication inhibitors |
| US11407715B2 (en) * | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| IL292970A (en) | 2019-11-15 | 2022-07-01 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| WO2022094816A1 (en) | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| WO2022094817A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Pharmaceutical formulation |
| CN113024440B (en) * | 2021-03-17 | 2023-05-16 | 凯莱英医药集团（天津）股份有限公司 | Method for continuously synthesizing substituted indole-2-carboxylic acid |
| AU2022304189A1 (en) | 2021-06-29 | 2024-02-15 | Janssen Pharmaceuticals, Inc. | Processes for the preparation of (s)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1 -(1h-indol-3-yl)ethenone derivatives |
| WO2023218285A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Treatment or prevention of dengue viral infection |
| CN115521307B (en) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | Preparation method of 5-halogeno-7-azaindole |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001520998A (en) | 1997-10-27 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | Morpholino-N-ethyl ester prodrug of indole sPLA2 inhibitor |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| US20050074457A1 (en) | 2001-12-12 | 2005-04-07 | Adeela Kamal | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| CA2593450A1 (en) | 2005-01-14 | 2006-07-20 | Genelabs Technologies, Inc. | Indole derivatives for treating viral infections |
| CA2597213A1 (en) | 2005-02-09 | 2006-09-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| FR2928645A1 (en) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | NOVEL CARBAZOLE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
| CN102056483A (en) | 2008-06-03 | 2011-05-11 | 西佳技术公司 | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| JP2012500260A (en) * | 2008-08-18 | 2012-01-05 | イェール・ユニヴァーシティー | MIF modulator |
| JP5559174B2 (en) | 2008-08-19 | 2014-07-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cold sensation-menthol receptor antagonist |
| TWI453207B (en) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| SG182478A1 (en) | 2010-01-15 | 2012-08-30 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| EP2552211A4 (en) | 2010-03-26 | 2013-10-23 | Glaxo Group Ltd | Indazolyl-pyrimidines as kinase inhibitors |
| JP5716205B2 (en) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | Composition for inhibiting glucosidase activity and screening method thereof |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| AP2016009122A0 (en) | 2013-10-23 | 2016-03-31 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| HUE040226T2 (en) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| DK3152317T3 (en) | 2014-06-04 | 2019-04-08 | Amgen Inc | Methods for Harvesting Mammalian Cell Cultures |
| JP6641299B2 (en) | 2014-06-04 | 2020-02-05 | フレッド ハッチンソン キャンサー リサーチ センター | Proliferation and engraftment of stem cells using Notch 1 and / or Notch 2 agonists |
| NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
| PL3201176T3 (en) | 2014-10-01 | 2019-06-28 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| CN107001265B (en) | 2014-10-01 | 2021-06-15 | 杨森制药公司 | Monosubstituted or disubstituted indoles as inhibitors of dengue virus replication |
| CN107002148B (en) | 2014-10-10 | 2023-02-17 | 新泽西鲁特格斯州立大学 | Polymerase chain reaction primer and probe for mycobacterium tuberculosis |
| JOP20150335B1 (en) * | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (en) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | BACE1 SELECTIVE INHIBITORS |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| ES2952726T3 (en) | 2015-07-22 | 2023-11-03 | Omeicos Therapeutics Gmbh | Metabolically strong CYP-eicosanoid analogues for the treatment of heart disease |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| PL3370698T3 (en) | 2015-11-03 | 2022-04-25 | Zoetis Services Llc | Sol-gel polymer composites and uses thereof |
| MY194647A (en) | 2016-03-31 | 2022-12-09 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| SG11201808138YA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole derivatives as dengue viral replication inhibitors |
| MA44498A (en) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | SUBSTITUTED INDOLINE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS |
| WO2017173384A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| JP7014731B2 (en) | 2016-04-01 | 2022-02-01 | シグナル ファーマシューティカルズ，エルエルシー | Substituted aminopurine compounds, their compositions, and therapeutic methods using them. |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA123912C2 (en) | 2016-04-01 | 2021-06-23 | Басф Се | Bicyclic compounds |
| EA201892200A1 (en) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | SUBSTITUTED DERIVATIVE COMPOUNDS OF INDOL AS AN INGIBITORS FOR DENG VIRUS REPLICATION INHIBITORS |
| TN2018000337A1 (en) | 2016-04-01 | 2020-01-16 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| US11407715B2 (en) | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| KR102625991B1 (en) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted indoline derivatives as dengue virus replication inhibitors |
-
2016
- 2016-05-03 JO JOP/2016/0086A patent/JOP20160086B1/en active
- 2016-05-04 EP EP16723965.6A patent/EP3294738B1/en active Active
- 2016-05-04 KR KR1020217011966A patent/KR102610493B1/en active IP Right Grant
- 2016-05-04 MX MX2020011156A patent/MX2020011156A/en unknown
- 2016-05-04 PE PE2021001440A patent/PE20221579A1/en unknown
- 2016-05-04 PE PE2017002377A patent/PE20180232A1/en unknown
- 2016-05-04 SI SI201631214T patent/SI3294738T1/en unknown
- 2016-05-04 LT LTEP16723965.6T patent/LT3294738T/en unknown
- 2016-05-04 MX MX2017014293A patent/MX2017014293A/en unknown
- 2016-05-04 CN CN202110222667.6A patent/CN113045476A/en active Pending
- 2016-05-04 BR BR112017023904-3A patent/BR112017023904A2/en not_active Application Discontinuation
- 2016-05-04 KR KR1020177031660A patent/KR102610491B1/en active IP Right Grant
- 2016-05-04 EA EA201792429A patent/EA034978B1/en unknown
- 2016-05-04 JP JP2017557923A patent/JP6752821B2/en active Active
- 2016-05-04 RS RS20210800A patent/RS62029B1/en unknown
- 2016-05-04 MD MDE20180272T patent/MD3294738T2/en unknown
- 2016-05-04 US US15/571,930 patent/US10696632B2/en active Active
- 2016-05-04 PL PL16723965T patent/PL3294738T3/en unknown
- 2016-05-04 WO PCT/EP2016/059975 patent/WO2016180696A1/en active Application Filing
- 2016-05-04 SG SG10201900315SA patent/SG10201900315SA/en unknown
- 2016-05-04 EP EP21159479.1A patent/EP3896072B1/en active Active
- 2016-05-04 UA UAA201711845A patent/UA121332C2/en unknown
- 2016-05-04 AU AU2016259677A patent/AU2016259677B2/en active Active
- 2016-05-04 ES ES16723965T patent/ES2877404T3/en active Active
- 2016-05-04 CR CR20170490A patent/CR20170490A/en unknown
- 2016-05-04 CA CA2981845A patent/CA2981845C/en active Active
- 2016-05-04 ES ES21159479T patent/ES2941674T3/en active Active
- 2016-05-04 CN CN202010168278.5A patent/CN111303000B/en active Active
- 2016-05-04 HU HUE16723965A patent/HUE054724T2/en unknown
- 2016-05-04 CN CN201680026606.XA patent/CN107873022B/en active Active
- 2016-05-04 DK DK16723965.6T patent/DK3294738T3/en active
- 2016-05-04 CR CR20200152A patent/CR20200152A/en unknown
- 2016-05-05 TW TW105113912A patent/TWI725969B/en active
- 2016-05-05 TW TW109121289A patent/TWI744963B/en active
- 2016-05-06 UY UY0001036674A patent/UY36674A/en active IP Right Grant
- 2016-05-06 UY UY0001039706A patent/UY39706A/en not_active Application Discontinuation
-
2017
- 2017-11-01 SV SV2017005557A patent/SV2017005557A/en unknown
- 2017-11-02 GT GT201700234A patent/GT201700234A/en unknown
- 2017-11-02 PH PH12017502000A patent/PH12017502000A1/en unknown
- 2017-11-05 IL IL255430A patent/IL255430B/en active IP Right Grant
- 2017-11-07 NI NI201700137A patent/NI201700137A/en unknown
- 2017-11-07 EC ECIEPI201773878A patent/ECSP17073878A/en unknown
- 2017-11-07 ZA ZA2017/07524A patent/ZA201707524B/en unknown
- 2017-11-07 CL CL2017002817A patent/CL2017002817A1/en unknown
- 2017-11-30 CO CONC2017/0012381A patent/CO2017012381A2/en unknown
-
2018
- 2018-09-13 HK HK18111747.3A patent/HK1252446A1/en unknown
- 2018-09-14 HK HK18111805.2A patent/HK1252496A1/en unknown
-
2020
- 2020-02-20 IL IL272814A patent/IL272814B/en active IP Right Grant
- 2020-04-13 JP JP2020071412A patent/JP6898493B2/en active Active
- 2020-05-05 ZA ZA2020/02435A patent/ZA202002435B/en unknown
- 2020-05-13 US US15/930,738 patent/US10919854B2/en active Active
- 2020-11-19 AU AU2020273314A patent/AU2020273314B2/en active Active
- 2020-12-31 US US17/139,703 patent/US11827602B2/en active Active
-
2021
- 2021-04-28 HR HRP20210675TT patent/HRP20210675T1/en unknown
- 2021-05-10 JO JOP/2021/0109A patent/JOP20210109A1/en unknown
- 2021-06-09 JP JP2021096927A patent/JP7132399B2/en active Active
- 2021-07-06 CY CY20211100607T patent/CY1124548T1/en unknown
-
2022
- 2022-03-25 EC ECSENADI202223220A patent/ECSP22023220A/en unknown
- 2022-08-24 JP JP2022133239A patent/JP7451626B2/en active Active
-
2023
- 2023-10-19 US US18/490,072 patent/US20240182414A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180232A1 (en) | DERIVED FROM INDOL MONO OR DISUSTITUTED AS INHIBITORS OF VIRAL REPLICATION OF DENGUE | |
| NI201700020A (en) | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | |
| AR108046A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE | |
| DOP2019000201A (en) | HIV INHIBITING COMPOUNDS | |
| CL2020001218A1 (en) | Useful compounds to inhibit cdk7. | |
| CO2020004301A2 (en) | 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| CL2017000742A1 (en) | Mono or disubstituted Indoles as inhibitors of dengue virus replication | |
| CL2018000697A1 (en) | Indole mono- or disubstituted derivatives as inhibitors of dengue viral replication. | |
| EA201790758A1 (en) | Derivatives of mono-or dislocated indo as an inhibitor of dengue virus replication | |
| CL2017001822A1 (en) | Mono or disubstituted indole derivatives as inhibitors of dengue virus replication | |
| EA201892200A1 (en) | SUBSTITUTED DERIVATIVE COMPOUNDS OF INDOL AS AN INGIBITORS FOR DENG VIRUS REPLICATION INHIBITORS | |
| EA201892216A1 (en) | SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION | |
| EA201691803A1 (en) | HUMAN PLASMA KALLIKREIN INHIBITORS | |
| AR111314A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| EA201692249A1 (en) | PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
| AR111820A1 (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
| CR20180495A (en) | INDOL DERIVATIVES REPLACED AS VIRAL REPLICATION INHIBITORS OF DENGUE | |
| UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| EA201890722A1 (en) | Derivatives of mono-or dislocated indo as an inhibitor of dengue virus replication | |
| CU24434B1 (en) | COMPOUNDS DERIVED FROM N- (1,5-DIMETHYL-3-OXO-2,3-DIHYDRO-1H-PIRAZOL-4-IL) -4-METHYL-5-ISOXAZOLE-3-CARBOXAMIDE ACTIVE AS SELECTIVE INHIBITORS OF SMURF-1 | |
| AR120158A2 (en) | SUBSTITUTED INDOL MONO OR DI DERIVATIVES AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
| AR102135A1 (en) | MONKEY OR DISABLED INDOLES AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
| AR113817A1 (en) | COMPOUNDS USEFUL TO INHIBIT CDK7 | |
| AR106029A1 (en) | DERIVATIVES OF INDOL MONO- OR DISABLED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE | |
| AR109850A2 (en) | METHODS TO TREAT INFECTIONS BY VIRUS FILOVIRIDAE |